A keratan sulfate disaccharide prevents inflammation and the progression of emphysema in murine models

Congxiao Gao, Reiko Fujinawa, Takayuki Yoshida, Manabu Ueno, Fumi Ota, Yasuhiko Kizuka, Tetsuya Hirayama, Hiroaki Korekane, Shinobu Kitazume, Toshitaka Maeno, Kazuaki Ohtsubo, Keiichi Yoshida, Yoshiki Yamaguchi, Bernd Lepenies, Jonas Aretz, Christoph Rademacher, Hiroki Kabata, Ahmed E. Hegab, Peter H. Seeberger, Tomoko BetsuyakuKozui Kida, Naoyuki Taniguchi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Emphysema is a typical component of chronic obstructive pulmonary disease (COPD), a progressive and inflammatory airway disease. However, no effective treatment currently exists. Here, we show that keratan sulfate (KS), one of the major glycosaminoglycans produced in the small airway, decreased in lungs of cigarette smoke-exposed mice. To confirm the protective effect of KS in the small airway, a disaccharide repeating unit of KS designated L4 ([SO3 --6]Galβ1–4[SO3 --6]GlcNAc) was administered to two murine models: elastase-induced-emphysema and LPS-induced exacerbation of a cigarette smoke-induced emphysema. Histological and microcomputed tomography analyses revealed that, in the mouse elastase-induced emphysema model, administration of L4 attenuated alveolar destruction. Treatment with L4 significantly reduced neutrophil influx, as well as the levels of inflammatory cytokines, tissue-degrading enzymes (matrix metalloproteinases), and myeloperoxidase in bronchoalveolar lavage fluid, suggesting that L4 suppressed inflammation in the lung. L4 consistently blocked the chemotactic migration of neutrophils in vitro. Moreover, in the case of the exacerbation model, L4 inhibited inflammatory cell accumulation to the same extent as that of dexamethasone. Taken together, L4 represents one of the potential glycan-based drugs for the treatment of COPD through its inhibitory action against inflammation.

Original languageEnglish
Pages (from-to)L268-L276
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Volume312
Issue number2
DOIs
Publication statusPublished - 2016 Dec 21

Fingerprint

Keratan Sulfate
Disaccharides
Emphysema
Inflammation
Pancreatic Elastase
Smoke
Tobacco Products
Chronic Obstructive Pulmonary Disease
Neutrophils
X-Ray Microtomography
Bronchoalveolar Lavage Fluid
Glycosaminoglycans
Matrix Metalloproteinases
Dexamethasone
Peroxidase
Polysaccharides
Pneumonia
Therapeutics
Cytokines
Lung

Keywords

  • Chronic obstructive pulmonary disease
  • Glycan
  • Keratan sulfate
  • L4

ASJC Scopus subject areas

  • Physiology
  • Pulmonary and Respiratory Medicine
  • Cell Biology
  • Physiology (medical)

Cite this

A keratan sulfate disaccharide prevents inflammation and the progression of emphysema in murine models. / Gao, Congxiao; Fujinawa, Reiko; Yoshida, Takayuki; Ueno, Manabu; Ota, Fumi; Kizuka, Yasuhiko; Hirayama, Tetsuya; Korekane, Hiroaki; Kitazume, Shinobu; Maeno, Toshitaka; Ohtsubo, Kazuaki; Yoshida, Keiichi; Yamaguchi, Yoshiki; Lepenies, Bernd; Aretz, Jonas; Rademacher, Christoph; Kabata, Hiroki; Hegab, Ahmed E.; Seeberger, Peter H.; Betsuyaku, Tomoko; Kida, Kozui; Taniguchi, Naoyuki.

In: American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 312, No. 2, 21.12.2016, p. L268-L276.

Research output: Contribution to journalArticle

Gao, C, Fujinawa, R, Yoshida, T, Ueno, M, Ota, F, Kizuka, Y, Hirayama, T, Korekane, H, Kitazume, S, Maeno, T, Ohtsubo, K, Yoshida, K, Yamaguchi, Y, Lepenies, B, Aretz, J, Rademacher, C, Kabata, H, Hegab, AE, Seeberger, PH, Betsuyaku, T, Kida, K & Taniguchi, N 2016, 'A keratan sulfate disaccharide prevents inflammation and the progression of emphysema in murine models', American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 312, no. 2, pp. L268-L276. https://doi.org/10.1152/ajplung.00151.2016
Gao, Congxiao ; Fujinawa, Reiko ; Yoshida, Takayuki ; Ueno, Manabu ; Ota, Fumi ; Kizuka, Yasuhiko ; Hirayama, Tetsuya ; Korekane, Hiroaki ; Kitazume, Shinobu ; Maeno, Toshitaka ; Ohtsubo, Kazuaki ; Yoshida, Keiichi ; Yamaguchi, Yoshiki ; Lepenies, Bernd ; Aretz, Jonas ; Rademacher, Christoph ; Kabata, Hiroki ; Hegab, Ahmed E. ; Seeberger, Peter H. ; Betsuyaku, Tomoko ; Kida, Kozui ; Taniguchi, Naoyuki. / A keratan sulfate disaccharide prevents inflammation and the progression of emphysema in murine models. In: American Journal of Physiology - Lung Cellular and Molecular Physiology. 2016 ; Vol. 312, No. 2. pp. L268-L276.
@article{382a84ef9a9741eaaa23a1d386bde277,
title = "A keratan sulfate disaccharide prevents inflammation and the progression of emphysema in murine models",
abstract = "Emphysema is a typical component of chronic obstructive pulmonary disease (COPD), a progressive and inflammatory airway disease. However, no effective treatment currently exists. Here, we show that keratan sulfate (KS), one of the major glycosaminoglycans produced in the small airway, decreased in lungs of cigarette smoke-exposed mice. To confirm the protective effect of KS in the small airway, a disaccharide repeating unit of KS designated L4 ([SO3 --6]Galβ1–4[SO3 --6]GlcNAc) was administered to two murine models: elastase-induced-emphysema and LPS-induced exacerbation of a cigarette smoke-induced emphysema. Histological and microcomputed tomography analyses revealed that, in the mouse elastase-induced emphysema model, administration of L4 attenuated alveolar destruction. Treatment with L4 significantly reduced neutrophil influx, as well as the levels of inflammatory cytokines, tissue-degrading enzymes (matrix metalloproteinases), and myeloperoxidase in bronchoalveolar lavage fluid, suggesting that L4 suppressed inflammation in the lung. L4 consistently blocked the chemotactic migration of neutrophils in vitro. Moreover, in the case of the exacerbation model, L4 inhibited inflammatory cell accumulation to the same extent as that of dexamethasone. Taken together, L4 represents one of the potential glycan-based drugs for the treatment of COPD through its inhibitory action against inflammation.",
keywords = "Chronic obstructive pulmonary disease, Glycan, Keratan sulfate, L4",
author = "Congxiao Gao and Reiko Fujinawa and Takayuki Yoshida and Manabu Ueno and Fumi Ota and Yasuhiko Kizuka and Tetsuya Hirayama and Hiroaki Korekane and Shinobu Kitazume and Toshitaka Maeno and Kazuaki Ohtsubo and Keiichi Yoshida and Yoshiki Yamaguchi and Bernd Lepenies and Jonas Aretz and Christoph Rademacher and Hiroki Kabata and Hegab, {Ahmed E.} and Seeberger, {Peter H.} and Tomoko Betsuyaku and Kozui Kida and Naoyuki Taniguchi",
year = "2016",
month = "12",
day = "21",
doi = "10.1152/ajplung.00151.2016",
language = "English",
volume = "312",
pages = "L268--L276",
journal = "American Journal of Physiology - Lung Cellular and Molecular Physiology",
issn = "1040-0605",
publisher = "American Physiological Society",
number = "2",

}

TY - JOUR

T1 - A keratan sulfate disaccharide prevents inflammation and the progression of emphysema in murine models

AU - Gao, Congxiao

AU - Fujinawa, Reiko

AU - Yoshida, Takayuki

AU - Ueno, Manabu

AU - Ota, Fumi

AU - Kizuka, Yasuhiko

AU - Hirayama, Tetsuya

AU - Korekane, Hiroaki

AU - Kitazume, Shinobu

AU - Maeno, Toshitaka

AU - Ohtsubo, Kazuaki

AU - Yoshida, Keiichi

AU - Yamaguchi, Yoshiki

AU - Lepenies, Bernd

AU - Aretz, Jonas

AU - Rademacher, Christoph

AU - Kabata, Hiroki

AU - Hegab, Ahmed E.

AU - Seeberger, Peter H.

AU - Betsuyaku, Tomoko

AU - Kida, Kozui

AU - Taniguchi, Naoyuki

PY - 2016/12/21

Y1 - 2016/12/21

N2 - Emphysema is a typical component of chronic obstructive pulmonary disease (COPD), a progressive and inflammatory airway disease. However, no effective treatment currently exists. Here, we show that keratan sulfate (KS), one of the major glycosaminoglycans produced in the small airway, decreased in lungs of cigarette smoke-exposed mice. To confirm the protective effect of KS in the small airway, a disaccharide repeating unit of KS designated L4 ([SO3 --6]Galβ1–4[SO3 --6]GlcNAc) was administered to two murine models: elastase-induced-emphysema and LPS-induced exacerbation of a cigarette smoke-induced emphysema. Histological and microcomputed tomography analyses revealed that, in the mouse elastase-induced emphysema model, administration of L4 attenuated alveolar destruction. Treatment with L4 significantly reduced neutrophil influx, as well as the levels of inflammatory cytokines, tissue-degrading enzymes (matrix metalloproteinases), and myeloperoxidase in bronchoalveolar lavage fluid, suggesting that L4 suppressed inflammation in the lung. L4 consistently blocked the chemotactic migration of neutrophils in vitro. Moreover, in the case of the exacerbation model, L4 inhibited inflammatory cell accumulation to the same extent as that of dexamethasone. Taken together, L4 represents one of the potential glycan-based drugs for the treatment of COPD through its inhibitory action against inflammation.

AB - Emphysema is a typical component of chronic obstructive pulmonary disease (COPD), a progressive and inflammatory airway disease. However, no effective treatment currently exists. Here, we show that keratan sulfate (KS), one of the major glycosaminoglycans produced in the small airway, decreased in lungs of cigarette smoke-exposed mice. To confirm the protective effect of KS in the small airway, a disaccharide repeating unit of KS designated L4 ([SO3 --6]Galβ1–4[SO3 --6]GlcNAc) was administered to two murine models: elastase-induced-emphysema and LPS-induced exacerbation of a cigarette smoke-induced emphysema. Histological and microcomputed tomography analyses revealed that, in the mouse elastase-induced emphysema model, administration of L4 attenuated alveolar destruction. Treatment with L4 significantly reduced neutrophil influx, as well as the levels of inflammatory cytokines, tissue-degrading enzymes (matrix metalloproteinases), and myeloperoxidase in bronchoalveolar lavage fluid, suggesting that L4 suppressed inflammation in the lung. L4 consistently blocked the chemotactic migration of neutrophils in vitro. Moreover, in the case of the exacerbation model, L4 inhibited inflammatory cell accumulation to the same extent as that of dexamethasone. Taken together, L4 represents one of the potential glycan-based drugs for the treatment of COPD through its inhibitory action against inflammation.

KW - Chronic obstructive pulmonary disease

KW - Glycan

KW - Keratan sulfate

KW - L4

UR - http://www.scopus.com/inward/record.url?scp=85012088603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012088603&partnerID=8YFLogxK

U2 - 10.1152/ajplung.00151.2016

DO - 10.1152/ajplung.00151.2016

M3 - Article

C2 - 28011617

AN - SCOPUS:85012088603

VL - 312

SP - L268-L276

JO - American Journal of Physiology - Lung Cellular and Molecular Physiology

JF - American Journal of Physiology - Lung Cellular and Molecular Physiology

SN - 1040-0605

IS - 2

ER -